MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity

Mitogen-activated protein kinase (MAPK) kinase (MEK) is an integral component of the RAS pathway and a therapeutic target in RAS-driven cancers. Although tumor responses to MEK inhibition are rarely durable, MEK inhibitors have shown substantial activity and durable tumor regressions when combined w...

Descripción completa

Detalles Bibliográficos
Autores principales: Yarchoan, Mark, Mohan, Aditya A., Dennison, Lauren, Vithayathil, Teena, Ruggieri, Amanda, Lesinski, Gregory B., Armstrong, Todd D., Azad, Nilofer S., Jaffee, Elizabeth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822709/
https://www.ncbi.nlm.nih.gov/pubmed/31671149
http://dx.doi.org/10.1371/journal.pone.0224600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822709/
https://www.ncbi.nlm.nih.gov/pubmed/31671149
http://dx.doi.org/10.1371/journal.pone.0224600

Ejemplares similares